[Drug-induced rhabdomyolysis].
Ueda
Shiro
S
Department of Drug Information and Communication, Graduate School of Pharmaceutical Sciences, Chiba University.
D058186:Acute Kidney Injury / Q000139:chemically induced; D000777:Anesthetics / Q000009:adverse effects; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D000978:Antiparkinson Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D019695:Glycyrrhizic Acid / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008305:Malignant Hyperthermia / Q000209:etiology; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D013997:Time Factors
D000777:Anesthetics; D047228:Angiotensin II Type 1 Receptor Blockers; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D019695:Glycyrrhizic Acid